$1.33
8.13% yesterday
Nasdaq, Sep 03, 10:15 pm CET
ISIN
US6904691010
Symbol
OVID

Ovid Therapeutics Inc. Stock price

$1.33
+0.83 167.88% 1M
+0.84 169.61% 6M
+0.40 42.44% YTD
+0.24 22.02% 1Y
-0.67 33.50% 3Y
-4.12 75.60% 5Y
-10.92 89.14% 10Y
-10.92 89.14% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.10 8.13%
ISIN
US6904691010
Symbol
OVID
Industry

Key metrics

Basic
Market capitalization
$87.5m
Enterprise Value
$49.1m
Net debt
positive
Cash
$38.4m
Shares outstanding
71.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.2 | 19.1
EV/Sales
7.4 | 10.7
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
74.0%
Return on Equity
-38.7%
ROCE
-60.7%
ROIC
-120.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$6.7m | $4.6m
EBITDA
$-39.3m | $-58.7m
EBIT
$-41.6m | $-48.9m
Net Income
$-38.2m | $-38.8m
Free Cash Flow
$-40.1m
Growth (TTM | estimate)
Revenue
1,087.5% | 702.5%
EBITDA
41.8% | 2.5%
EBIT
39.0% | 21.0%
Net Income
-28.1% | -46.8%
Free Cash Flow
24.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-591.2% | -1,282.3%
EBIT
-625.0%
Net
-574.0% | -848.1%
Free Cash Flow
-602.3%
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
2.5%
Employees
23
Rev per Employee
$20.0k
Show more

Is Ovid Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Ovid Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Ovid Therapeutics Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Ovid Therapeutics Inc. forecast:

Buy
92%
Hold
8%

Financial data from Ovid Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6.65 6.65
1,088% 1,088%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
28% 28%
321%
- Research and Development Expense 27 27
31% 31%
405%
-39 -39
42% 42%
-591%
- Depreciation and Amortization 2.25 2.25
309% 309%
34%
EBIT (Operating Income) EBIT -42 -42
39% 39%
-625%
Net Profit -38 -38
28% 28%
-574%

In millions USD.

Don't miss a Thing! We will send you all news about Ovid Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ovid Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
22 days ago
Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline asset OV4071, the first ever oral KCC2 direct activator, is completing an IND-enabling package; Ovid anticipates f...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company's management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. About Ovid Therapeutics Ovid Therapeutics Inc. ...
Neutral
GlobeNewsWire
2 months ago
Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs
More Ovid Therapeutics Inc. News

Company Profile

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Head office United States
CEO Jeremy Levin
Employees 23
Founded 2014
Website ovidrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today